Citadel Advisors’s Indaptus Therapeutics INDP Stock Holding History

Citadel Advisors’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6	Closed	-$3K	–	11202
2020 Q3	$3K	Buy	+6	New	+$4.41K	﹤0.01%	9974
2019 Q4	–	Sell	-8	Closed	-$13K	–	9404
2019 Q3	$13K	Sell	8 -9	-53%	-$26.8K	﹤0.01%	9016
2019 Q2	$167K	Buy	+17	New	+$214K	﹤0.01%	8305

Other funds holding INDP

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Citadel Advisors's INDP Position: Q1 2026 in Review

Citadel Advisors opened a new position in Indaptus Therapeutics (INDP) in Q1 2026: 39,018 shares worth $71K. The stake represents ﹤0.01% of the portfolio and ranks #12243 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INDP as recently as Q3 2024.

Citadel Advisors first reported a position in INDP in Q3 2019 and has held it in 14 quarters since. The position peaked at $160K in Q4 2020. 6 funds tracked by Wall St. Rank hold INDP as of Q1 2026.

Citadel Advisors held 39,018 shares of Indaptus Therapeutics worth $71K as of Q1 2026.
Indaptus Therapeutics was a new Citadel Advisors position in Q1 2026.
Indaptus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12243 holding.
Citadel Advisors first reported a position in Indaptus Therapeutics in Q3 2019 and has held it in 14 quarters since.
Citadel Advisors's Indaptus Therapeutics position peaked at $160K in Q4 2020.
6 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.